Evidence map›Paper›PMID 35032102›Full record

ArticleESC heart failure2022

Outcomes after heart transplantation in patients with cardiac sarcoidosis.

Rabea Asleh, Alexandros Briasoulis, Ilias Doulamis, Hilmi Alnsasra, Aspasia Tzani, Paulino Alvarez, Toshiki Kuno, Polydoros Kampaktsis, Sudhir Kushwaha

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESC heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 3 countries.

Rabea AslehDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.
Alexandros BriasoulisDivision of Cardiovascular Medicine, Section of Heart failure and Transplantation, University of Iowa, Iowa City, IA, USA.
Ilias DoulamisDepartment of Cardiac Surgery, Boston's Children Hospital, Harvard Medical School, Boston, MA, USA.
Hilmi AlnsasraDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.
Aspasia TzaniDepartment of Cardiac Surgery, Boston's Children Hospital, Harvard Medical School, Boston, MA, USA.
Paulino AlvarezDepartment of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA.
Toshiki KunoDepartment of Medicine Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel, New York, NY, USA.
Polydoros KampaktsisDivision of Cardiology, New York University Langone Medical Center, New York, NY, USA.
Sudhir KushwahaDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.
Boston Children's Hospital · USCleveland Clinic · USFrontier Science Foundation-Hellas · GRHadassah Medical Center · ILMayo Clinic · USMayo Clinic in Florida · USMount Sinai Beth Israel · USNYU Langone Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe number of patients with sarcoidosis requiring heart transplantation (HT) is increasing. The aim of this study was to evaluate outcomes of isolated HT in patients with sarcoid cardiomyopathy and compare them to recipients with non-ischaemic restrictive or dilated cardiomyopathy. METHODS AND

resultsAdult HT recipients were identified in the UNOS Registry between 1990 and 2020. Patients were grouped according to diagnosis. The cumulative incidences for the all-cause mortality and rejection were compared using Fine and Gray model analysis, accounting for re-transplantation as a competing risk. Rejection was evaluated using logistic regression analysis. We also reviewed characteristics and outcomes of all HT recipients with previous diagnosis of sarcoid cardiomyopathy from a single centre. A total of 30 160 HT recipients were included in the present study (n = 239 sarcoidosis, n = 1411 non-ischaemic restrictive cardiomyopathy, and n = 28 510 non-ischaemic dilated cardiomyopathy). During a total of 194 733 patient-years, all-cause mortality at the latest follow-up was not significantly different when comparing sarcoidosis to non-ischaemic dilated cardiomyopathy [adjusted subhazard ratio (aSHR) 1.46, 95% confidence intervals (CIs): 0.9-2.4, P = 0.12] or restrictive cardiomyopathy (aSHR 1.12, 95% CI: 0.65-1.95, P = 0.67). Accordingly, multivariable analysis suggested that 1 year mortality was not significantly different between sarcoidosis and non-ischaemic dilated cardiomyopathy (aSHR 1.56, 95% CI: 0.9-2.7, P = 0.12) or restrictive cardiomyopathy (aSHR 1.15, 95% CI: 0.61-2.18, P = 0.66). No differences were observed regarding 30 day mortality, treated and hospitalized acute rejection, and 30 day death from graft failure after HT. Thirty-day mortality did not improve significantly in more recent HT eras whereas there was a trend towards improved 1 year mortality in the latest HT era (P = 0.06). Data from the single-centre case review showed excellent long-term outcomes with sirolimus-based immunosuppression.

conclusionsShort-term and long-term post HT outcomes among patients with sarcoid cardiomyopathy are similar to those with common types of non-ischaemic cardiomyopathy.

Indexed as

Cardiomyopathy, RestrictiveHeart TransplantationSarcoidosisAdultHumansRetrospective StudiesTreatment OutcomeCardiac sarcoidosisDilated cardiomyopathyHeart transplantationOutcomesRestrictive cardiomyopathy

Identifiers

PMID35032102
PMCPMC8934937
OpenAlexW4206490354

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.